Treatment with sulforaphane can dramatically increase the levels of recombinant Solute Carrier Family 7 Member 11, ferritin, and GSH levels through the activation of the redox-sensitive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), thereby alleviating DCM. This evidence concerns the gene SLC17A1 and familial dilated cardiomyopathy.